Related Experiment Video
Updated: Apr 21, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Comprehensive analysis of temozolomide treatment for patients with glioma
Wen-Bing Yang1, Bian-Zhi Xing, Hua Liang
1Department of Radiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China
Background:
This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma.
Methods:
Clinical studies evaluating the efficacy and safety of temozolomide based regimens for patients with glioma were identified using a predefined search strategy. Pooled response rates (RRs) were calculated.
Results:
In temozolomide based regimens, 5 clinical studies including 152 patients with advanced glioma were considered eligible for inclusion. Four clinical studies included temozolomide. Systematic analysis suggested that, in all patients, pooled CR was 21% (32/152) , and PR was 21% (32/152). Grade 3/4 toxicity included neutropenia, thrombocytopenia, and anemia. No grade 3 or 4 renal or liver toxicity was observed. No treatment related death occurred with temozolomide based treatment.
Conclusion:
This systematic analysis suggests that temozolomide based regimens are associated with mild response rate and acceptable toxicity for treatment of glioma patients.
